Haodi Wu1,2,3, Huaxiao Yang1,2,3, June-Wha Rhee1,2,3, Joe Z Zhang1,2,3, Chi Keung Lam1,2,3, Karim Sallam1,2,3, Alex C Y Chang1,4, Ning Ma1,2,3, Jaecheol Lee1,2,3, Hao Zhang1,2,3, Helen M Blau1,4, Donald M Bers5, Joseph C Wu1,2,3. 1. Stanford Cardiovascular Institute, Stanford University School of Medicine, 265 Campus Drive, Stanford, CA, USA. 2. Division of Cardiology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. 3. Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA. 4. Department of Microbiology and Immunology, Baxter Laboratory for Stem Cell Biology, Stanford University School of Medicine, Stanford, CA, USA. 5. Department of Pharmacology, University of California, 451 Health Sciences Drive, Davis, CA, USA.
Abstract
AIMS: Diastolic dysfunction (DD) is common among hypertrophic cardiomyopathy (HCM) patients, causing major morbidity and mortality. However, its cellular mechanisms are not fully understood, and presently there is no effective treatment. Patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) hold great potential for investigating the mechanisms underlying DD in HCM and as a platform for drug discovery. METHODS AND RESULTS: In the present study, beating iPSC-CMs were generated from healthy controls and HCM patients with DD. Micropatterned iPSC-CMs from HCM patients showed impaired diastolic function, as evidenced by prolonged relaxation time, decreased relaxation rate, and shortened diastolic sarcomere length. Ratiometric Ca2+ imaging indicated elevated diastolic [Ca2+]i and abnormal Ca2+ handling in HCM iPSC-CMs, which were exacerbated by β-adrenergic challenge. Combining Ca2+ imaging and traction force microscopy, we observed enhanced myofilament Ca2+ sensitivity (measured as dF/Δ[Ca2+]i) in HCM iPSC-CMs. These results were confirmed with genome-edited isogenic iPSC lines that carry HCM mutations, indicating that cytosolic diastolic Ca2+ overload, slowed [Ca2+]i recycling, and increased myofilament Ca2+ sensitivity, collectively impairing the relaxation of HCM iPSC-CMs. Treatment with partial blockade of Ca2+ or late Na+ current reset diastolic Ca2+ homeostasis, restored diastolic function, and improved long-term survival, suggesting that disturbed Ca2+ signalling is an important cellular pathological mechanism of DD. Further investigation showed increased expression of L-type Ca2+channel (LTCC) and transient receptor potential cation channels (TRPC) in HCM iPSC-CMs compared with control iPSC-CMs, which likely contributed to diastolic [Ca2+]i overload. CONCLUSION: In summary, this study recapitulated DD in HCM at the single-cell level, and revealed novel cellular mechanisms and potential therapeutic targets of DD using iPSC-CMs. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Diastolic dysfunction (DD) is common among hypertrophic cardiomyopathy (HCM) patients, causing major morbidity and mortality. However, its cellular mechanisms are not fully understood, and presently there is no effective treatment. Patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) hold great potential for investigating the mechanisms underlying DD in HCM and as a platform for drug discovery. METHODS AND RESULTS: In the present study, beating iPSC-CMs were generated from healthy controls and HCM patients with DD. Micropatterned iPSC-CMs from HCM patients showed impaired diastolic function, as evidenced by prolonged relaxation time, decreased relaxation rate, and shortened diastolic sarcomere length. Ratiometric Ca2+ imaging indicated elevated diastolic [Ca2+]i and abnormal Ca2+ handling in HCM iPSC-CMs, which were exacerbated by β-adrenergic challenge. Combining Ca2+ imaging and traction force microscopy, we observed enhanced myofilament Ca2+ sensitivity (measured as dF/Δ[Ca2+]i) in HCM iPSC-CMs. These results were confirmed with genome-edited isogenic iPSC lines that carry HCM mutations, indicating that cytosolic diastolic Ca2+ overload, slowed [Ca2+]i recycling, and increased myofilament Ca2+ sensitivity, collectively impairing the relaxation of HCM iPSC-CMs. Treatment with partial blockade of Ca2+ or late Na+ current reset diastolic Ca2+ homeostasis, restored diastolic function, and improved long-term survival, suggesting that disturbed Ca2+ signalling is an important cellular pathological mechanism of DD. Further investigation showed increased expression of L-type Ca2+channel (LTCC) and transient receptor potential cation channels (TRPC) in HCM iPSC-CMs compared with control iPSC-CMs, which likely contributed to diastolic [Ca2+]i overload. CONCLUSION: In summary, this study recapitulated DD in HCM at the single-cell level, and revealed novel cellular mechanisms and potential therapeutic targets of DD using iPSC-CMs. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Xiaojun Lian; Cheston Hsiao; Gisela Wilson; Kexian Zhu; Laurie B Hazeltine; Samira M Azarin; Kunil K Raval; Jianhua Zhang; Timothy J Kamp; Sean P Palecek Journal: Proc Natl Acad Sci U S A Date: 2012-05-29 Impact factor: 11.205
Authors: Juan E Camacho Londoño; Qinghai Tian; Karin Hammer; Laura Schröder; Julia Camacho Londoño; Jan C Reil; Tao He; Martin Oberhofer; Stefanie Mannebach; Ilka Mathar; Stephan E Philipp; Wiebke Tabellion; Frank Schweda; Alexander Dietrich; Lars Kaestner; Ulrich Laufs; Lutz Birnbaumer; Veit Flockerzi; Marc Freichel; Peter Lipp Journal: Eur Heart J Date: 2015-06-11 Impact factor: 29.983
Authors: Sherif F Nagueh; Otto A Smiseth; Christopher P Appleton; Benjamin F Byrd; Hisham Dokainish; Thor Edvardsen; Frank A Flachskampf; Thierry C Gillebert; Allan L Klein; Patrizio Lancellotti; Paolo Marino; Jae K Oh; Bogdan Alexandru Popescu; Alan D Waggoner Journal: Eur Heart J Cardiovasc Imaging Date: 2016-07-15 Impact factor: 6.875
Authors: Haodi Wu; Jaecheol Lee; Ludovic G Vincent; Qingtong Wang; Mingxia Gu; Feng Lan; Jared M Churko; Karim I Sallam; Elena Matsa; Arun Sharma; Joseph D Gold; Adam J Engler; Yang K Xiang; Donald M Bers; Joseph C Wu Journal: Cell Stem Cell Date: 2015-06-18 Impact factor: 24.633
Authors: Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer Journal: Eur Heart J Date: 2016-05-20 Impact factor: 29.983
Authors: Li Pang; Philip Sager; Xi Yang; Hong Shi; Frederick Sannajust; Mathew Brock; Joseph C Wu; Najah Abi-Gerges; Beverly Lyn-Cook; Brian R Berridge; Norman Stockbridge Journal: Circ Res Date: 2019-10-10 Impact factor: 17.367
Authors: Shane Rui Zhao; Mengcheng Shen; Chelsea Lee; Yanjun Zha; Julio V Guevara; Matthew T Wheeler; Joseph C Wu Journal: Stem Cell Res Date: 2021-11-12 Impact factor: 2.020
Authors: Chrishan J A Ramachandra; Jasper Chua; Shuo Cong; Myu Mai Ja Kp; Winston Shim; Joseph C Wu; Derek J Hausenloy Journal: Cardiovasc Res Date: 2021-02-22 Impact factor: 10.787
Authors: Lorenzo R Sewanan; Jinkyu Park; Michael J Rynkiewicz; Alice W Racca; Nikolaos Papoutsidakis; Jonas Schwan; Daniel L Jacoby; Jeffrey R Moore; William Lehman; Yibing Qyang; Stuart G Campbell Journal: J Gen Physiol Date: 2021-07-28 Impact factor: 4.086